ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 770

Circulating Levels of iC3b and C3 Correlate with Sledai-2K Responder Index-50 (S2K RI-50) Disease Activity Scores: The Castle (Complement Activation Signatures in Systemic Lupus Erythematosus) Study

Alfred Kim1, Vibeke Strand2, Nancy Mathis1, Deepali Sen3, Jonathan Miner3, Elizabeth Schramm1, Robin Bruchas4, Nick Staten4, Paul Olson4, Chad Stiening4 and John Atkinson1, 1Rheumatology, Washington University School of Medicine, Saint Louis, MO, 2Adjunct, Division of Immunology / Rheumatology, Stanford University, Palo Alto, CA, 3Division of Rheumatology, Washington University School of Medicine, Saint Louis, MO, 4Kypha, Inc., Saint Louis, MO

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Biomarkers, complement and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: A major unmet need in SLE is the identification
of a biomarker that consistently tracks with disease activity. One current
approach is measuring complement activation by evaluating consumption of serum
C3 and C4. However, since they are acute phase reactants (Gabay
& Kushner, NEJM, 340:448, 1999), interpretation of these
levels is challenging as serum levels may not decrease until late in a disease
flare (Sturfelt & Sjoholm,
Int Arch Allergy Appl
Immunol
, 75:75,
1984). iC3b is a proteolytically derived molecule of
C3b, and increases with complement activation. iC3b/C3
ratio measures complement consumption relative to production, which may provide
for a more accurate assessment of complement activation. We hypothesize that
blood iC3b and iC3b/C3 levels will provide as a more specific and reliable
marker of complement activation and disease activity in SLE.

Methods: 90 adult SLE patients were enrolled in this observational study,
encompassing 188 longitudinal visits. C3 and C4 were measured by nephelometry; iC3b using the Kypha
lateral flow assay test. Linear models analysis was used to generate predictive
models of S2K RI-50 scores using iC3b, C3, iC3b/C3 ratio, C4, anti-dsDNA Abs, ESR, and CRP from single visit data. Mixed model
repeated measures analysis was used to evaluate longitudinal data.

Results: Using single visit data, blood levels of iC3b, C3, iC3b/C3 ratio,
C4, and ESR each correlated with SLE disease activity (Table 1). Linear models
analysis yielded a predictive model using iC3b/C3 ratio, C4, and ESR. In the
longitudinal dataset, after modeling for variance structure, S2K RI-50 scores
increased by 0.52 for every 1 unit increase in iC3b/C3 ratios (Table 2). C4 was
also found to mildly influence S2K RI-50 scores.

Conclusion: iC3b/C3 ratios correlated with S2K RI-50 scores and linear model
analysis confirmed the predictive value of iC3b to S2K RI-50 scores. After
adjusting for both correlation and other covariates, the longitudinal data
further established a significant relationship between iC3b/C3 ratios and SLE
disease activity. These data warrant further investigation of iC3b as a
potential biomarker for disease activity in SLE.

Description: Macintosh HD:Users:alfredkim:Documents:WashU:Research:Posters/Presentations:2015.11 ACR (San Francisco):CASTLE:Tables mod.tiff


Disclosure: A. Kim, Kypha, Inc., 2,Amgen, Janssen, Pfizer, 5; V. Strand, Abbvie, Alder, Amgen, Anthera, AstraZeneca, BiogenIdec, Bristol-Myers Squibb, Genentech, GSK, Janssen, MerckSerono, Novartis, Pfizer Inc, Sanofi-Aventis, and UCB, 2; N. Mathis, Kypha, Inc., 5; D. Sen, None; J. Miner, None; E. Schramm, Kypha, Inc., 3; R. Bruchas, Kypha, Inc., 3; N. Staten, Kypha, Inc., 3; P. Olson, Kypha, Inc., 3; C. Stiening, Kypha, Inc., 3; J. Atkinson, Kypha, Inc., 6.

To cite this abstract in AMA style:

Kim A, Strand V, Mathis N, Sen D, Miner J, Schramm E, Bruchas R, Staten N, Olson P, Stiening C, Atkinson J. Circulating Levels of iC3b and C3 Correlate with Sledai-2K Responder Index-50 (S2K RI-50) Disease Activity Scores: The Castle (Complement Activation Signatures in Systemic Lupus Erythematosus) Study [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/circulating-levels-of-ic3b-and-c3-correlate-with-sledai-2k-responder-index-50-s2k-ri-50-disease-activity-scores-the-castle-complement-activation-signatures-in-systemic-lupus-erythematosus-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/circulating-levels-of-ic3b-and-c3-correlate-with-sledai-2k-responder-index-50-s2k-ri-50-disease-activity-scores-the-castle-complement-activation-signatures-in-systemic-lupus-erythematosus-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology